The organization of the regulatory system of feeding and of the parallel metabolic changes is schematized by a cyclical cartoon depicting the 8 phases of regulation. As I proposed in 1974, the cycle starts with the detection by hypothalamic sensors of decrease of the ATP/ADP/AMP turnover that reflects the post-prandial slow decline of general metabolic rate. That detection is translated into a signal of hunger. Experimental evidence is provided. Once initiated, this 'basic' signal follows the 7 remaining steps of the cycle, particularly the steps 2 and 4, where it receives multiple 'modulating' positive and negative signals (particularly peptides) that inform the central regulator, on the state of peripheral organs such as the adipocytes, stomach, intestine, and liver, on the outside world like day/light and on the available foods. Particular attention is given to the homeostatic and "homeoreutic" (see definition in the text) regulation of adipose reserves that are announced to brain specialized glio-neuronal "lipo-counters". The role of insulin alongside leptin is shown. The conception of a part of the above mechanisms postulates and shows that some specialized glio-neuronal populations in the antero-ventral hypothalamus share metabolic properties along with somatic cells. Finally, the signal resulting from the algebraic sum of the main (the metabolic) signal and of the modulating pluses and minuses (peptides) leaves the integrative units and reaches the efferent phases (steps 5 and 6) that finish by inducing both metabolic adjustments and consequently food intake. The last steps (4 to 8) are only shortly commented.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.physbeh.2011.04.058 | DOI Listing |
Neuro Oncol
October 2024
Division of Oncology, Department of Medicine 1, Medical University, Vienna, Austria ORCID iD 0000-0003-3541-2315.
The standard of care for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a major part of the standard treatment, however, the predictive significance of most of the targets for treatment in systemic cancer are less well established in central nervous system (CNS) tumors . In 2023 the EANO Guideline Committee presented evidence based recommendations for rational testing of molecular targets for targeted treatments.
View Article and Find Full Text PDFFree Neuropathol
January 2024
Department of Neuropathology, University Hospital Erlangen, Germany.
Neuropathology-based studies in neurosurgically resected brain tissue obtained from carefully examined patients with focal epilepsies remain a treasure box for excellent insights into human neuroscience, including avenues to better understand the neurobiology of human brain organization and neuronal hyperexcitability at the cellular level including glio-neuronal interaction. It also allows to translate results from animal models in order to develop personalized treatment strategies in the near future. A nice example of this is the discovery of a new disease entity in 2017, termed mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy or MOGHE, in the frontal lobe of young children with intractable seizures.
View Article and Find Full Text PDFActa Neuropathol
June 2023
Department of Neuropathology, Partner of the European Reference Network (ERN) EpiCARE, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, 91054, Germany.
Exome-wide sequencing studies recently described PTPN11 as a novel brain somatic epilepsy gene. In contrast, germline mutations of PTPN11 are known to cause Noonan syndrome, a multisystem disorder characterized by abnormal facial features, developmental delay, and sporadically, also brain tumors. Herein, we performed a deep phenotype-genotype analysis of a comprehensive series of ganglioglioma (GG) with brain somatic alterations of the PTPN11/KRAS/NF1 genes compared to GG with common MAP-Kinase signaling pathway alterations, i.
View Article and Find Full Text PDFRedox Biol
June 2023
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK. Electronic address:
The transcription factor Nrf2 and its repressor Keap1 mediate cell stress adaptation by inducing expression of genes regulating cellular detoxification, antioxidant defence and energy metabolism. Energy production and antioxidant defence employ NADH and NADPH respectively as essential metabolic cofactors; both are generated in distinct pathways of glucose metabolism, and both pathways are enhanced by Nrf2 activation. Here, we examined the role of Nrf2 on glucose distribution and the interrelation between NADH production in energy metabolism and NADPH homeostasis using glio-neuronal cultures isolated from wild-type, Nrf2-knockout and Keap1-knockdown mice.
View Article and Find Full Text PDFCurr Health Sci J
December 2021
Department of Pathology, '"Carol Davila" University of Medicine and Pharmacy, National Institute for Mother and Child Health "Alessandrescu-Rusescu" Bucharest, Romania.
Gangliogliomas are extremely rare central nervous tumors composed of an admixture of glial and neuroepithelial elements. Gangliogliomas mainly affect the temporal lobe and occur in the pediatric population. There are several controversies in the scientific literature regarding these tumors, which debuted with the exclusion of grade II gangliogliomas in the 2006 edition of the current World Health Organization (WHO) classification.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!